Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline

• Published in: ACS chemical neuroscience Vol. 10; no. 3; pp. 1753 - 1764
• Main Authors: Thorn, Catherine A, Moon, Joshua, Bourbonais, Clinton A, Harms, John, Edgerton, Jeremy R, Stark, Eda, Steyn, Stefanus J, Butter, Christopher R, Lazzaro, John T, O’Connor, Rebecca E, Popiolek, Michael
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 20.03.2019
• Subjects: Acetylcholine - metabolism; Acetylcholine - pharmacology; Animals; CA1 Region, Hippocampal - drug effects; CA1 Region, Hippocampal - metabolism; Corpus Striatum - drug effects; Corpus Striatum - metabolism; Hippocampus - drug effects; Hippocampus - metabolism; Muscarinic Agonists - pharmacology; Prefrontal Cortex - drug effects; Prefrontal Cortex - metabolism; Pyridines - pharmacology; Receptor, Muscarinic M1 - metabolism; Thiadiazoles - pharmacology; Xanomeline; striatum; hippocampus; electrophysiology; muscarinic acetyl­choline receptor; in vivo potency; biochemistry; muscarinic acetylcholine receptor

Preclinical and clinical data suggest that muscarinic acetyl­choline receptor activation may be therapeutically beneficial for the treatment of schizophrenia and Alzheimer’s diseases. This is best exemplified by clinical observations with xanomeline, the efficacy of which is thought to be mediated t...